In:
Chemotherapy, S. Karger AG, Vol. 61, No. 2 ( 2016), p. 93-98
Abstract:
〈 b 〉 〈 i 〉 Background: 〈 /i 〉 〈 /b 〉 S-1, a novel oral fluoropyrimidine, is active in the treatment of non-small cell lung cancer (NSCLC). However, data on S-1 for elderly patients with NSCLC are insufficient. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 Eligibility criteria were no prior chemotherapy, stage IIIB or IV NSCLC, performance status 0-1, age 〉 70 years, and adequate hematological, hepatic, and renal functions. Patients received S-1 (40 mg/m 〈 sup 〉 2 〈 /sup 〉 twice a day) for 28 consecutive days. This schedule was repeated every 6 weeks. The primary end point was the tumor response rate. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 Thirty-two patients were enrolled and 31 patients were evaluable for response. The patients' median age was 80 years (range: 71-88). The response rate was 22.6% (95% CI: 11-38). Neutropenia, anemia, thrombocytopenia, febrile neutropenia, and diarrhea of grade ≥3 occurred in 6, 6, 10, 3, and 3%, respectively. 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 In elderly patients with previously untreated advanced NSCLC, S-1 appears to be well tolerated and demonstrates encouraging activity.
Type of Medium:
Online Resource
ISSN:
0009-3157
,
1421-9794
Language:
English
Publisher:
S. Karger AG
Publication Date:
2016
detail.hit.zdb_id:
1482111-4
SSG:
15,3
Permalink